<DOC>
	<DOCNO>NCT00764829</DOCNO>
	<brief_summary>We interested patient-specific factor may affect balance recipient cell donor cell patient receive stem cell transplant . We look way patient 's body break two drug , fludarabine mycophenolate mofetil , two drug affect patient 's body .</brief_summary>
	<brief_title>Blood Samples Evaluate Biomarkers Donor Chimerism</brief_title>
	<detailed_description />
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<criteria>Diagnosed hematologic disease malignancy Scheduled receive nonablative conditioning fludarabine total body irradiation Donor wellmatched high resolution DNA technique . Scheduled receive postgrafting immunosuppression oral MMF ( CellCept ) oral calcineurin inhibitor . Age &gt; 18 year time enrollment . Exclusion criterion : Diagnosed immunodeficiency disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>hematopoietic stem cell transplantation</keyword>
	<keyword>fludarabine</keyword>
	<keyword>mycophenolate mofetil</keyword>
	<keyword>mycophenolic acid</keyword>
	<keyword>biomarkers</keyword>
</DOC>